$-0.58 EPS Expected for Akcea Therapeutics, Inc. (AKCA)

July 14, 2018 - By Robert Sims

Analysts expect Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report $-0.58 EPS on August, 14.They anticipate $0.31 EPS change or 114.81 % from last quarter’s $-0.27 EPS. After having $-0.44 EPS previously, Akcea Therapeutics, Inc.’s analysts see 31.82 % EPS growth. The stock increased 0.72% or $0.2 during the last trading session, reaching $27.8. About 157,312 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $2.38 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

More notable recent Akcea Therapeutics, Inc. (NASDAQ:AKCA) news were published by: Benzinga.com which released: “48 Biggest Movers From Yesterday” on June 20, 2018, also Fool.com with their article: “Is Ionis Pharmaceuticals, Inc. a Buy?” published on July 12, 2018, Benzinga.com published: “38 Stocks Moving In Tuesday’s Mid-Day Session” on June 19, 2018. More interesting news about Akcea Therapeutics, Inc. (NASDAQ:AKCA) were released by: Streetinsider.com and their article: “Ionis Pharma (IONS), Akcea (AKCA) Announce NEJM Published Results from Pivotal Study of TEGSEDI for Treatment …” published on July 05, 2018 as well as Seekingalpha.com‘s news article titled: “Ionis Pharma’s inotersen OK’d in Europe for hATTR” with publication date: July 11, 2018.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.